Dividend30 May 2026, 03:51 pm
Titan Biotech Approves FY26 Audited Results, Recommends ₹0.50 Dividend
AI Summary
Titan Biotech Ltd's Board of Directors approved the audited financial results for the year ended March 31, 2026. The board recommended a dividend of ₹0.50 per equity share, subject to shareholder approval. They also approved the re-appointment of M/s Sanjay Kumar Garg & Associates as Cost Auditor, pending shareholder ratification. Mr. Pankaj Kumar Gupta was appointed as Scrutinizer for the upcoming Annual General Meeting.
Key Highlights
- Approved audited financial results for the year ended March 31, 2026.
- Recommended a dividend of ₹0.50 per equity share, subject to shareholder approval.
- Re-appointed M/s Sanjay Kumar Garg & Associates as Cost Auditor.
- Appointed Mr. Pankaj Kumar Gupta as Scrutinizer for the 34th AGM.
- Board meeting commenced at 03:00 P.M. and concluded at 03:34 P.M.
Price Impact
More from TITANBIO